The role of the HER-2/neu oncogene in gynecologic cancers

Journal of the Society for Gynecologic Investigation

Volumn 3, Issue 3, 1996, Pages 99-105

  Cirisano, Frank D ^a   Karlan, Beth Y ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

gene targeted therapy; gynecologic cancer; HER 2 neu; tumor marker

Indexed keywords

COMPLEMENTARY DNA; RECEPTOR ANTIBODY; RECEPTOR PROTEIN; TUMOR MARKER;

BREAST CANCER; CANCER SURVIVAL; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE THERAPY; GYNECOLOGIC CANCER; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; ONCOGENE NEU; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TRANSCRIPTION REGULATION;

BREAST NEOPLASMS; ENDOMETRIAL NEOPLASMS; FALLOPIAN TUBE NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; GENITAL NEOPLASMS, FEMALE; HUMANS; MEDLINE; OVARIAN NEOPLASMS; PROGNOSIS; RECEPTOR, ERBB-2; SURVIVAL RATE; TRANSCRIPTION, GENETIC; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 0029962038     PISSN: 10715576     EISSN: None     Source Type: Journal    
DOI: 10.1016/1071-5576(96)00001-9     Document Type: Review

References (54)

1. Padhy LC, Shih C, Cowing D, Finkelstein R, Weinberg RA. Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas. Cell 1982;28:865-71.
2. Popescu NC, King CR, Kraus MH. Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. Genomics 1989;4:362-6.
3. Bargman CI, Hung MC, Weinberg RA. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 1986;319:226-30.
4. Borg A, Tandon AK, Sigurdsson H, et al. HER-2/neu amplification predicts poor survival in node-negative breast cancer. Cancer Res 1990;50:4332-7.
5. Tsuda H, Hirohashi S, Shimosato Y, et al. Immunohistochemical study on overexpression of c-cerbB-2 protein in human breast cancer: Its correlation with gene amplification and long-term survival of patients. Jpn J Cancer Res 1990;81:327-32.
6. Berchuck A, Kamel A, Whitaker R, et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990;50:4087-91.
7. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 1989;244:707-12.
8. Hetzel DJ, Wilson TO, Keeney GL, Roche PC, Cha SS, Podratz KC. HER-2/neu expression: A major prognostic factor in endometrial cancer. Gynecol Oncol 1992;47:179-85.
9. Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, Norton L. Immunohistochemical detection of HER-2/neu in patients with axillary lymph node negative breast carcinoma. Cancer 1995;75:1320-6.
10. Higashiyama S, Abraham JA, Miller JF, Klagsburn M. A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science 1991;251:936-9.
11. Burgess TL, Ross SL, Qian YX, Brankow D, Hu S. Biosynthetic processing of neu differentiation factor. Glycosylation trafficking, and regulated cleavage from the cell surface. J Biol Chem 1995; 270:19188-96.
12. Wada T, Qian XL, Greene MI. Intermolecular association of the p185 neu protein and EGF receptor modulates EGF receptor function. Cell 1990;61:1337-47.
13. Yarden Y. Agonistic antibodies stimulate the kinase encoded by the neu protooncogene in living cells but the oncogenic mutant is constitutively active. Proc Natl Acad Sci U S A 1990;87:2569-73.
14. c-neu density govern receptor interactions and tyrosine kinase activation. Proc Natl Acad Sci U S A 1994;91: 1711-5.
15. Chazin VR, Kaleko M, Miller AD, Slamon DJ. Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. Oncogene 1992;7:1859-66.
16. Scott GK, Robles R, Park JW, et al. A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells. Mol Cell Biol 1993; 13:2247-57.
17. Bacus SS, Huberman E, Chin K, et al. A ligand for the erbB-2 oncogenic product (gp30) induces differentiation of human breast cancer cells. Cell Growth Differ 1992;3:401-11.
18. Lin YJ, Clinton GM. A soluble protein related to the HER-2 proto-oncogene product is released from human breast carcinoma cells. Oncogene 1991;6:639-43.
19. Bosher JM, Williams T, Hurst HC. The developmentally regulated transcription factor AP-2 is involved in c-erbB-2 overexpression in human mammary carcinoma. Proc Natl Acad Sci U S A 1995;92:744-7.
20. Brock ML, Shapiro DJ. Estrogen stabilizes vitellogenin mRNA against cytoplasmic degredation. Cell 1983;34:207-14.
21. Karlan BY, Jones J, Slamon DJ, Lagasse LD. Glucocorticoids stabilize HER-2/neu messenger RNA in human epithelial ovarian carcinoma cells. Gynecol Oncol 1994;53:70-7.
22. Pietras RJ, Arboleda J, Reese DM, et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995;10:2435-46.
23. Rubin SC, Finstad CL, Wong GY, Almadrones L, Plante M, Lloyd KO. Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: A multivariate analysis. Am J Obstet Gynecol 1993;168:162-9.
24. Haldane JS, Hird V, Hughes CM, Gullick WJ. c-erbB-2 oncogene expression in ovarian cancer. J Pathol 1990;162:231-7.
25. Wilkinson N, Todd N, Buckley CH, Gusterson BA, Fox H. An immunohistochemical study of the incidence and significance of c-erbB-2 oncoprotein overexpression in ovarian neoplasia. Int J Gynecol Cancer 1991;1:258-9.
26. Rubin SC, Finstad CL, Federici MG, Scheiner L, Lloyd KO, Hoskins WJ. Revalence and significance of HER-2/neu expression in early epithelial ovarian cancer. Cancer 1994;73:1456-9.
27. Buller RE, Anderson B, Connor JP, Robinson R. Familial ovarian cancer. Gynecol Oncol 1993;51:160-6.
28. Berchuck A, Rodriquez G, Kinney RB, et al. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol 1991;164:15-21.
29. Pisani AL, Barbuto DA, Chen D, Ramos L, Lagasse LD, Karlan BY. HER-2/neu, p53, and DNA analyses as prognosticators for survival in endometrial carcinoma. Obstet Gynecol 1995;85: 729-34.
30. Clark GM, McGuire WL. Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 1991;51:944-8.
31. Ali IU, Campbell G, Lidereau R, Callahan R. Lack of evidence for the prognostic significance of c-erbB-2 amplification in human breast carcinoma. Onco Res 1988;3:139-46.
32. Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989;7:1120-8.
33. Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. J Clin Oncol 1993;11:1936-42.
34. Ro JS, El-Naggar A, Ro JY, et al. c-erbB2 amplification in node-negative human breast cancer. Cancer Res 1989;49: 6941-4
35. Van de Vijver MJ, Peterse JL, Mooi WJ, et al. Neu protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 1988;319:1239-45.
36. Parkes HC, Lillycrop K, Howell A, Craig RK. c-erbB2 mRNA expression in human breast tumors: Comparison with c-erbB2 DNA amplification and correlation with prognosis. Br J Cancer 1990;61:39-45.
37. Lacy MQ, Hartmann LC, Keeney GL, et al. c-erbB-2 and p53 expression in fallopian tube carcinoma. Cancer 1995;75:2891-6.
38. Pinion SB, Kennedy JH, Miller RW, MacLean AB. Oncogene expression in cervical intraepithelial neoplasia and invasive cancer of the cervix. Lancet 1991;337:819-20.
39. Mitra AB, Murty VVVS, Pratap M, Sodhani P, Chaganti RSK. ERBB2 (HER-2/neu) oncogene is frequently amplified in squamous cell carcinoma of the uterine cervix. Cancer Res 1994;54: 637-9.
40. Jennings TS, Dottino PR, Mandeli JP, Segna RA, Kelliher K, Cohen CJ. Growth factor expression in normal peritoneum of patients with gynecologic carcinoma. Gynecol Oncol 1994;55: 190-7.
41. Zabrecky JR, Lam T, McKenzie SJ, Carney W. The extracellular domain of p185 neu is released from the surface of human breast carcinoma cell, SK-BR-3. J Biol Chem 1991;266:1716-20.
42. Langton BC, Crenshaw MC, Chao LA, Stuart SG, Akita RW, Jackson JE. An antigen immunologically related to the external domain of gp185 is shed from nude mouse tumors overexpressing the c-erbB-2 (HER-2/neu) oncogene. Cancer Res 1991;51: 2593-98.
43. Carney WP, Hamer PJ, Petit D, et al. Detection and quantitation of the human neu oncoprotein. J Tumor Marker Oncol 1991;6: 53-72.
44. neu in human ovarian cancer. Cancer 1993;71:3942-6.
45. Meden H, Marx D, Fattahi A, et al. Elevated serum levels of a c-erbB-2 oncogene product in ovarian cancer patients and in pregnancy. J Cancer Res Clin Oncol 1994;120:378-81.
46. Cane P, Azen C, Lopez E, Platt LD, Karlan BY. Tumor marker trends in asymptomatic women at risk for ovarian cancer: Relevance for ovarian cancer screening. Gynecol Oncol 1995;57: 240-5.
47. Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 1990;5:953-62.
48. Niehans GA, Singleton TP, Dykoski D, Kiang DT. Stability of HER-2/neu expression over time and at multiple metastatic sites. J Natl Cancer Inst 1993;85:1230-5.
49. HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992;89:4285-9.
50. Townsend A, Bodmer H. Antigen recognition by class I-restricted lymphocytes. Annu Rev Immunol 1989;7:601-24.
51. Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlain TJ. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER-2/neu-derived peptide. Proc Natl Acad Sci U S A 1995;92:432-6.
52. Huang SK, Mayhew EM, Gilani S, Lasic DD, Martin FJ, Papahadjopoulos D. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res 1992;52:6774-81.
53. Park JW, Hong K, Carter P, et al. Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc Natl Acad Sci USA 1995;92:1327-31.
54. Vaughn JP, Iglehart JD, Demirdji S, et al. Antisense DNA down-regulation of the ERBB2 oncogene measured by a flow cytometric assay. Proc Natl Acad Sci U S A 1995;92:8338-42.